Collegium Pharmaceutical (COLL) Q1 2026 earnings review
AZSTARYS Acquisition Overshadows Seasonal Softness
Collegium delivered a solid Q1 with total revenue up 9% YoY to $193.5M. While top-line growth is decelerating compared to 2025's 24% pace, JORNAY PM remains a potent growth engine, surging 36% YoY. As previously guided, JORNAY PM saw a sequential decline from Q4 due to annual deductible resets, but underlying demand remains robust. The real game-changer is the $650M acquisition of AZSTARYS, which mitigates long-term generic risks and transforms Collegium into a diversified, multi-asset ADHD franchise. The pain portfolio remains a stable cash cow, but flat Nucynta sales hint at emerging generic pressures.
🐂 Bull Case
The $650M acquisition of AZSTARYS adds a highly complementary asset, extending revenue visibility into the late 2030s and leveraging Collegium's recently expanded 180-rep neuropsychiatry sales force.
Despite Q1 gross-to-net headwinds, JORNAY PM prescriptions reached an all-time high of over 206,000 (+14% YoY) and the prescriber base expanded 17% YoY to 30,000.
🐻 Bear Case
Nucynta revenue was flat YoY at $47.0M. Stripping out the $2.7M profit share from the newly launched Hikma authorized generic (AG), branded sales actually contracted, signaling the beginning of generic cannibalization.
GAAP operating expenses grew 14% YoY, outpacing the 9% revenue growth. Integrating AZSTARYS could further pressure short-term EBITDA margins.
⚖️ Verdict: 🟢
Bullish. Management executed exactly on their telegraphed Q1 seasonality expectations while deploying their massive cash stockpile into a highly strategic acquisition that completely changes the company's terminal value narrative.
Key Themes
Transformative AZSTARYS Acquisition
Collegium is acquiring AZSTARYS for $650M in cash (plus up to $135M in milestones). This is a textbook deployment of the cash generated by the legacy pain portfolio. AZSTARYS immediately diversifies the ADHD dependency away from just JORNAY PM, extends the company's exclusivity runway into the late 2030s, and leverages the exact same commercial infrastructure built over the last 12 months. It shifts Collegium from a 'pain company with an ADHD asset' to a legitimate neuropsychiatry platform.
JORNAY PM Market Penetration Accelerating
While sequentially lower, JORNAY PM's 36% YoY growth to $38.9M demonstrates accelerating market acceptance. The structural groundwork—expanding the sales force to 180 reps and executing the 'Embrace Your Sparkle' campaign with Paris Hilton—is translating into record prescription volumes (206,000) and a broadening prescriber base (30,000). The thesis that evening dosing is a highly marketable differentiator remains intact.
Pain Portfolio: Stable Cash Cow
The legacy pain portfolio continues to fulfill its mandate: providing stable cash flows to fund BD and ADHD expansion. The portfolio generated $154.6M (+4% YoY). Belbuca grew 2% and Xtampza ER grew 7%. While not a growth engine, this durability provides a powerful financial backstop, funding $57.1M in Q1 operating cash flow.
Q1 Seasonality & Gross-to-Net Pressures
As telegraphed in the Q4 call, Q1 is structurally the weakest quarter due to insurance deductible resets creating higher patient out-of-pocket costs. JORNAY PM revenue reversed sequentially, dropping from $45.9M in 25Q4 to $38.9M in 26Q1. While anticipated, it highlights the brand's vulnerability to seasonal gross-to-net fluctuations, which will remain a recurring Q1 hurdle.
Nucynta Cannibalization Underway
The Nucynta franchise was completely flat YoY at $47.0M. Crucially, this figure includes $2.7M from the Hikma Authorized Generic (AG) launch. Excluding the AG profit share, the branded Nucynta product shrank. The transition to maximizing value via the AG is working, but it confirms the underlying branded volume is beginning to erode.
Other KPIs
Stable trajectory. Grew 9% YoY, perfectly matching the 9% revenue growth and indicating that operating leverage is holding steady despite the 11% YoY increase in adjusted operating expenses. Cash generation remains elite, with $57.1M generated from operations.
Accelerating significantly from $2.4M in 25Q1. This improvement was aided by a reduction in interest expense ($15.8M vs $20.7M a year ago) as the company aggressively paid down debt throughout 2025. This deleveraging cycle has perfectly positioned the balance sheet for the $650M AZSTARYS cash outlay.
Guidance
Decelerating. Reaffirmed guidance implies a ~5.7% YoY growth rate at the midpoint, a sharp slowdown from the 24% growth achieved in FY25. Note: This guidance excludes any contribution from AZSTARYS, meaning a significant upward revision is guaranteed post-close.
Stable. Implies roughly 31% YoY growth at the midpoint vs FY25's $148.9M. Given the $38.9M achieved in the seasonally weak Q1, the company is highly on track to hit or beat this target as volume typically builds through the back-to-school season.
Stable. Reaffirmed guidance sits essentially flat compared to the $460.5M delivered in FY25. This reflects deliberate reinvestment into the commercial infrastructure rather than passing all gross profit to the bottom line.
Key Questions
AZSTARYS Financial Integration
With the AZSTARYS acquisition expected to close in Q2 and be immediately accretive to adjusted EBITDA, what is the expected revenue run-rate for the asset in the second half of 2026, and how much incremental commercial spend is required to support it?
Nucynta AG Cannibalization Dynamics
With the Hikma AG contributing $2.7M in Q1, how much branded Nucynta volume was cannibalized by this launch? What is the expected equilibrium point between branded erosion and AG profit share for the remainder of the year?
Capital Deployment Post-M&A
The $650M cash outlay for AZSTARYS will consume your current cash balance of $421.8M and likely require drawing on the $980M credit facility. How does this altered leverage profile impact your willingness to execute on the existing $150M share repurchase authorization?